References
- BenEzra D, Cohen E. Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 1986; 70: 589–592
- Beh$cLet H. $UUber rezidivierende Aphthose, durch ein Virus verursachte Geschwure am Mund, am Auge und an den Genitalien. Derm Wschr 1937; 36: 1152–1157
- Mamo J G. The rate of visual loss in Behçet's disease. Arch Ophthalmol 1970; 84: 451–452
- O'Duffy J D. Suggested criteria for the diagnosis of Behçet's disease. J Rheumatol 1974; 1(Suppl)1, 18
- International Study Group for Behçet's disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 35: 1078–1080
- Hijikata K, Masuda K. Visual prognosis in Behçet's disease: effects of cyclophosphamide and colchicine. Jpn J Ophthalmol 1978; 22: 506–519
- Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporin versus colchicine and long term open study of cyclosporin in Behçet's disease. Lancet 1989; 1: 1093–1096
- Ezra Ben D, Cohen E. Treatment in ocular Behçet's disease. Behçet's Disease. Basic and Clinical Aspects, J D O'Duffy, E Kokmen. Marcel Dekker, Inc, New York 1991; 619–623
- Nussenblatt R B, Palestine A G, Chan C C, et al. Effectiveness of cyclosporine therapy for Behçet's disease. Arthritis Rheumatol 1985; 28: 671–679
- Binder A I, Graham E M, Sanders M D, et al. Cyclosporin A in the treatment of severe Behçet's uveitis. Br J Rheumatol 1987; 26: 285–291
- Yazici H, Pazarli H, Barnes C, et al. A controlled trial of azathioprine in Behçet's syndrome. N Eng J Med 1990; 322: 281–285
- Mamo J G. Treatment of Behçet's disease with Chlorambucil. Br J Ophthalmol 1976; 94: 580–583
- Charteris D, Barton K, McCartney A, Lightman S. CD4+ T-lymphocytes in ocular Behçet's disease. Autoimmunity 1992; 12: 201–206
- Lightman S, Towler H. Immunopathology and altered immunity in posterior uveitis in man: a review. Curr Eye Res 1992; 11(Suppl)11–15
- Savion S, Grover S, Kawano Y, Caspi R R. Uveitogenicity of T cell lines in the rat does not correlate with their production of TNF, IFN, or IL3. Invest Ophthalmol Vis Sci 1992; 33: 952
- Dinning W J, Graham E, Denman A M. A retrospective study of therapeutic response and visual outcome in patients with eye disease. Behçet's Disease. Basic and Clinical Aspects, J D O'Duffy, E Kokmen. Marcel Dekker, Inc, New York 1991; 597–601
- BenEzra D, Barak V, Kalichman I, Maftzir G. Interleukin-2 receptor in Behçet's disease-effect of Cyclosporin A. Invest Ophthalmol Vis Sci 1990; 32: 935
- BenEzra D, Maftzir G, Kalichman I, Barak V. Serum levels of Interleukin-2 receptor in ocular Behçet's disease. Am J Ophthalmol 1993; 115: 26–30
- Arocker-Mettinger E, Asenbauer T, Ulbrich S, Grabner G. Serum interleukin-2 receptor levels in uveitis. Curr Eye Res 1990; 9(Suppl)25–29
- Adachi K, Kumamoto T, Araki S. Interleukin-2 receptor levels indicate relapse in multiple sclerosis. Lancet 1989; i: 559–560
- Lightman S, Calder V, Greenwood J, Towler H MA. The pathogenic role of T cells in intraocular inflammation. Chibret Int J Ophthalmol, (in press)